Setting Up a Pharmaceutical Company in India

Industry Overview: India's Pharmaceutical Powerhouse

India is the world's third-largest pharmaceutical producer by volume and the largest supplier of generic medicines globally, accounting for approximately 20% of the world's generic drug output by volume. The country is also the world's largest vaccine producer, supplying over 60% of global vaccine demand. India's pharmaceutical market stood at approximately USD 55-58 billion in 2025 and is projected to reach USD 120-130 billion by 2030, growing at a robust CAGR of 10-12%.

The sector is a significant contributor to India's economy, ranking third in global pharmaceutical production and employing over 2.9 million people. India has approximately 3,000 pharma companies with over 10,500 manufacturing units spread across the country, including 850+ WHO-pre-qualified manufacturing facilities. Key pharma hubs include Hyderabad (bulk drugs and APIs), Mumbai-Pune corridor (formulations and R&D), Ahmedabad (formulations), Baddi in Himachal Pradesh (formulations), and Visakhapatnam (bulk drugs).

The pharmaceutical sector has attracted over USD 21.5 billion in cumulative FDI since April 2000, representing approximately 3% of total FDI equity inflows into India. India's competitive advantage lies in its low manufacturing costs (30-40% lower than the US and Europe), a large pool of skilled scientists and pharmacists, robust regulatory infrastructure aligned with global standards, and an extensive raw material supply chain for Active Pharmaceutical Ingredients (APIs). The government's PLI scheme for pharmaceuticals, with a total outlay of INR 15,000 crore, is further strengthening India's position as a global pharmaceutical manufacturing hub.

FDI Policy & Entry Routes for Pharmaceuticals

India's FDI policy for the pharmaceutical sector distinguishes between greenfield and brownfield investments, applying different rules to each category.

Greenfield Projects (New Manufacturing): 100% FDI is permitted under the automatic route for greenfield pharmaceutical projects. This means a foreign company can set up a new pharmaceutical manufacturing facility, research centre, or formulation plant with full foreign ownership without requiring prior government approval. This liberalised policy has made India one of the most attractive destinations globally for pharmaceutical greenfield investment.

Brownfield Projects (Existing Entities): For brownfield investments, including mergers, acquisitions, and investments in existing pharmaceutical companies, up to 74% FDI is permitted under the automatic route. FDI beyond 74% in brownfield pharma requires prior approval through the government approval route from the Department of Pharmaceuticals. This distinction is designed to protect domestic pharmaceutical manufacturers while still encouraging foreign investment in the sector.

Conditions for Brownfield Investments: For brownfield FDI beyond 74%, the government evaluates whether the production of drugs listed in the National List of Essential Medicines (NLEM) will be maintained for the domestic market and whether R&D expenditure will be maintained at existing levels. These conditions ensure that foreign acquisitions do not compromise India's drug security or reduce investments in pharmaceutical research.

Medical Devices: 100% FDI under the automatic route is permitted for manufacturing of medical devices with no distinction between greenfield and brownfield. This includes diagnostic equipment, surgical instruments, implants, and medical electronics, offering a simpler entry path for foreign companies focused on medical technology.

Investors from countries sharing a land border with India must obtain prior government approval under Press Note 3 (2020) for any investment, regardless of the amount or greenfield/brownfield classification. For expert guidance on structuring pharmaceutical FDI transactions, consult our FDI advisory team.

Required Licences & Regulatory Bodies

The pharmaceutical sector in India is regulated through a dual system of central and state authorities. Obtaining the correct licences before commencing operations is mandatory and carries severe penalties for non-compliance.

The CDSCO acts as the National Regulatory Authority (NRA) under the Drugs and Cosmetics Act, 1940, overseeing new drug approvals, clinical trial permissions, import licences, and quality standards. At the state level, State Drug Regulatory Authorities manage manufacturing licences through the Online National Drugs Licensing System (ONDLS). Since 2025, all applications must be filed through the ONDLS digital portal. CDSCO's SUGAM portal streamlines applications with real-time tracking, auto-approval mechanisms if queries remain unresolved within 30 days, and electronic document management.

GMP compliance is mandatory for all pharmaceutical manufacturers. Facilities must adhere to Schedule M of the Drugs and Cosmetics Rules, which has been progressively aligned with WHO-GMP standards. An on-site inspection by the drug regulatory authority is required before a manufacturing licence is granted, and periodic inspections continue throughout the licence validity period (typically 3-5 years).

Entity Structure Options for Pharmaceuticals

Choosing the right corporate vehicle is critical for pharmaceutical companies entering India, as it affects regulatory eligibility, FDI compliance, tax treatment, and operational flexibility.

Private Limited Company: This is the most common structure for pharmaceutical ventures in India. It provides limited liability, allows foreign shareholding up to 100% for greenfield projects, and is eligible for all drug manufacturing licences and regulatory approvals. Most pharma-specific incentives, including the PLI scheme, require the applicant to be a company registered under the Companies Act, 2013. Register your entity through our Private Limited Company registration service.

Wholly Owned Subsidiary (WOS): Global pharmaceutical companies like Pfizer, Novartis, AstraZeneca, and GSK operate in India through wholly owned subsidiaries. This structure provides complete operational control, ring-fenced liability, and a clean corporate structure for compliance with both Indian regulations and parent company governance standards. Set up your foreign subsidiary in India with our end-to-end service.

Joint Venture (JV): A JV with an established Indian pharmaceutical company can be advantageous for foreign investors looking to leverage existing manufacturing infrastructure, distribution networks, and regulatory relationships. This structure is particularly useful for brownfield investments where FDI beyond 74% requires government approval. The Indian partner's existing licences and market access can significantly reduce time-to-market.

Limited Liability Partnership (LLP): While LLPs offer lower compliance overhead, they are less common in pharmaceuticals due to restrictions on FDI in LLPs and the preference of regulatory authorities for company structures. LLPs may be suitable for pharmaceutical consulting, clinical research organisations (CROs), or contract research activities where regulatory licences are held by partner entities.

For a detailed comparison of entity types, refer to our Private Limited vs LLP comparison guide.

Tax Incentives & Government Schemes

The Indian government has introduced multiple schemes to boost pharmaceutical manufacturing, reduce import dependence for APIs, and encourage R&D investment.

PLI Scheme for Pharmaceuticals: With a total outlay of INR 15,000 crore (approximately USD 2 billion) from FY 2020-21 to FY 2028-29, this scheme incentivises domestic manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs). Incentive rates are 10% on incremental sales for FY 2022-26, 8% for FY 2026-27, and 6% for FY 2027-28 across three product categories. The government disbursed INR 604 crore under the scheme in H1 FY25, with total disbursements of approximately INR 6,800 crore by April 2024 across 53 greenfield fermentation and chemical-synthesis projects.

PLI Scheme for Medical Devices: A separate PLI scheme with an outlay of INR 3,420 crore incentivises manufacturing of high-value medical devices including cancer care equipment, radiology and imaging equipment, implants, and anesthetics with a 5% incentive on incremental sales.

R&D Tax Deductions (Section 35(2AB)): Companies with DSIR-approved in-house R&D facilities can claim a 100% deduction on R&D expenditure, covering clinical drug trials, regulatory approval costs, and patent application expenses. Capital expenditure on R&D (excluding land) is fully deductible. In-house R&D units in pharmaceuticals can import specified goods duty-free. The R&D facility must be approved by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology.

SEZ Benefits: Pharmaceutical units set up in Special Economic Zones enjoy 100% income tax exemption on export profits for the first 5 years, 50% for the next 5 years, and a further 50% of ploughed-back profits for 5 more years. Additional benefits include duty-free import of raw materials, exemption from GST on inter-unit supplies, and simplified customs procedures. India has several pharma-focused SEZs in Hyderabad, Visakhapatnam, and Ahmedabad.

Concessional Corporate Tax: New manufacturing companies can avail an effective tax rate of 17.16% under Section 115BAB, a significant reduction from the standard 25.17% rate. This benefit is available for greenfield pharmaceutical manufacturing companies incorporated after October 2019.

Key Compliance Requirements for Pharmaceuticals

Pharmaceutical companies in India face sector-specific compliance obligations beyond general corporate law requirements. Non-compliance can result in licence suspension, product recalls, and criminal penalties.

Drug Price Control (DPCO 2013): The National Pharmaceutical Pricing Authority (NPPA) controls prices of scheduled formulations listed in the National List of Essential Medicines (NLEM). The Drug Price Control Order mandates ceiling prices for 748 formulations (as of April 2025), with maximum retail prices adjusted annually based on the Wholesale Price Index (WPI). Manufacturers must revise prices within 15 days of NPPA notification, and penalties for overcharging can include refund of excess amounts with interest.

GMP Compliance (Schedule M): All manufacturing facilities must comply with Schedule M of the Drugs and Cosmetics Rules, which covers facility design, equipment qualification, process validation, quality control testing, documentation practices, and personnel training. Schedule M has been progressively aligned with WHO-GMP standards and is a prerequisite for obtaining and maintaining manufacturing licences.

Pharmacovigilance: Under the Pharmacovigilance Programme of India (PvPI), pharmaceutical companies must report Adverse Drug Reactions (ADRs) through designated monitoring centres. The Drugs and Cosmetics (Amendment) Rules, 2020 expanded the responsibility of marketers alongside manufacturers for drug quality and safety compliance. Companies must maintain a pharmacovigilance system and designate a qualified person responsible for pharmacovigilance.

Environmental Compliance: Pharmaceutical manufacturing, particularly API and bulk drug production, falls under the purview of environmental regulations. Companies must obtain Environmental Clearance from the Ministry of Environment, consent to establish and consent to operate from the State Pollution Control Board, and comply with waste management regulations including the Hazardous and Other Wastes Management Rules.

FEMA and FDI Compliance: Companies with foreign investment must comply with FEMA regulations including filing Form FC-GPR for share allotments, annual FLA returns, pricing guidelines for share transfers, and downstream investment notifications. Engage our FEMA compliance team for end-to-end regulatory support.

Setting Up Pharmaceutical Operations in India

Establishing a pharmaceutical manufacturing or distribution operation in India involves multiple regulatory touchpoints. Here is a practical step-by-step guide with realistic timelines and costs.

Step 1: Entity Incorporation (2-3 weeks): Register a Private Limited Company through the SPICe+ portal. For a pharma company, ensure the Memorandum of Association includes pharmaceutical manufacturing, trading, and R&D in its objects clause. You will need at least 2 directors (one must be an Indian resident director) and 2 shareholders.

Step 2: Foreign Investment Compliance (2-4 weeks): For greenfield projects, file Form FC-GPR with RBI through an Authorised Dealer Bank within 30 days of share allotment. For brownfield investments exceeding 74%, submit the government approval application to the Department of Pharmaceuticals through the Foreign Investment Facilitation Portal (FIFP).

Step 3: Site Selection & Factory Setup (3-6 months): Select a manufacturing site with adequate infrastructure, water supply, and effluent treatment capacity. Key locations include pharma parks and SEZs in Hyderabad, Visakhapatnam, Ahmedabad, and Baddi. Obtain land approvals, building permits, and environmental clearance. Apply for consent to establish from the State Pollution Control Board.

Step 4: Drug Licensing (2-3 months): Apply for the Drug Manufacturing Licence (Form 25 for formulations, Form 28 for sterile products) through the state's ONDLS portal. Submit facility plans, equipment lists, and personnel qualifications. The State Drug Inspector will conduct an on-site inspection of the facility before granting the licence. Licence validity is typically 3-5 years, renewable upon application.

Step 5: GMP Certification & Quality Systems (2-4 months): Implement GMP-compliant quality management systems covering all aspects of manufacturing, testing, and documentation. Apply for WHO-GMP certification through CDSCO if targeting export markets. Engage qualified personnel including a qualified pharmacist as the responsible person for manufacturing.

Step 6: Product Registration (Ongoing): For each drug product, obtain manufacturing permission from the State Drug Controller (for drugs listed in the Indian Pharmacopoeia) or from CDSCO/DCGI (for new drugs or drugs not manufactured in India). Submit stability data, analytical methods, and bioequivalence studies as required.

Typical costs: Company incorporation costs INR 10,000-15,000 in government fees. Drug Manufacturing Licence fees are typically INR 3,000-10,000 per product category. The major investment is in manufacturing infrastructure, ranging from INR 50 lakh for a small formulation unit to INR 2 crore or more for a sterile manufacturing facility. Total setup costs including land, building, equipment, and regulatory compliance typically range from INR 1 crore for distribution operations to INR 10-50 crore for a full-scale manufacturing facility.

Case Studies: Major Foreign Players in India's Pharmaceutical Sector

India hosts major operations of virtually every global pharmaceutical company, demonstrating the country's strategic importance as both a manufacturing hub and a growing consumer market.

AstraZeneca: The British-Swedish pharmaceutical giant operates a Global Capability Center (GCC) in India established in 2014, now employing over 3,100 professionals across Bengaluru and Chennai. Investments exceed USD 50 million. In November 2024, AstraZeneca inaugurated its new Global Innovation and Technology Centre in Chennai, the company's largest GCC worldwide, expected to create 4,000 high-quality jobs. India handles drug development, IT services, global business services, and R&D for the company.

Novartis: With over 8,000 associates in India, Novartis's Indian operations support drug development, manufacturing, supply and quality, HR, and legal functions. India accounts for 20% of Novartis's global employees through its GCC operations. The company plans to hire 500-700 people annually to further grow its Indian presence, focusing on high-value functions including data science, clinical operations, and regulatory affairs.

Pfizer: Pfizer India operates through a listed subsidiary (Pfizer Ltd, BSE/NSE listed) and maintains a Global Drug Development Centre in Chennai employing approximately 1,000 people. The Chennai centre is a strategic R&D hub focusing on complex sterile injectable drugs, innovative formulations, small molecule research, and API development. Pfizer India reported revenues exceeding INR 2,500 crore for FY 2024-25.

GSK (GlaxoSmithKline): GSK has a long-standing presence in India dating back to 1924. The company operates through GSK Pharmaceuticals (prescription medicines) and maintains a large technology and operations hub. GSK's India operations are integral to the company's global supply chain, particularly in vaccine manufacturing and distribution.

Sanofi: The French pharmaceutical company operates in India through Sanofi India Limited (a listed entity) with manufacturing facilities in Goa and Ankleshwar (Gujarat). Sanofi's India operations focus on vaccines, consumer healthcare, and specialty care products, leveraging India's cost-effective manufacturing capabilities for global supply.

These examples illustrate that India's pharmaceutical sector offers multiple entry strategies for foreign companies, from wholly owned manufacturing subsidiaries to R&D-focused GCCs and listed entity structures. With 45% of global drug discovery and development, 60% of regulatory affairs, and 54% of pharmacovigilance operations running from India, the country has become an indispensable node in global pharmaceutical value chains.

Frequently Asked Questions